NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Down 30.0% in February

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) saw a significant drop in short interest during the month of February. As of February 13th, there was short interest totaling 392,037 shares, a drop of 30.0% from the January 29th total of 559,856 shares. Based on an average daily volume of 152,582 shares, the days-to-cover ratio is presently 2.6 days. Based on an average daily volume of 152,582 shares, the days-to-cover ratio is presently 2.6 days.

NeuroSense Therapeutics Stock Performance

Shares of NASDAQ NRSN traded up $0.01 during trading hours on Friday, reaching $0.91. The stock had a trading volume of 40,902 shares, compared to its average volume of 172,336. NeuroSense Therapeutics has a twelve month low of $0.68 and a twelve month high of $2.60. The business’s fifty day moving average is $0.92 and its two-hundred day moving average is $1.05.

Hedge Funds Weigh In On NeuroSense Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP acquired a new stake in shares of NeuroSense Therapeutics during the 3rd quarter valued at about $26,000. Jane Street Group LLC acquired a new stake in NeuroSense Therapeutics during the second quarter valued at approximately $54,000. Yorkville Advisors Global LP bought a new stake in shares of NeuroSense Therapeutics in the 4th quarter valued at approximately $77,000. Finally, Squarepoint Ops LLC raised its holdings in shares of NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares in the last quarter. 1.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on NRSN shares. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a research report on Monday, December 22nd. Finally, Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.